Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sperling, Adam
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study	Recruiting	3	1400	Europe, Canada, Japan, US, RoW	Previously treated CAR-T patients	Novartis Pharmaceuticals, University of Pennsylvania	Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program	02/36	02/36
NCT05172596 / 2021-003747-22: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma	Active, not recruiting	2	147	Europe, Canada, Japan, US, RoW	PHE885	Novartis Pharmaceuticals, Novartis Pharma AG	Multiple Myeloma	06/25	06/25
NCT04318327: BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma	Active, not recruiting	1	96	US, RoW	PHE885	Novartis Pharmaceuticals	Multiple Myeloma	02/26	02/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sperling, Adam
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study	Recruiting	3	1400	Europe, Canada, Japan, US, RoW	Previously treated CAR-T patients	Novartis Pharmaceuticals, University of Pennsylvania	Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program	02/36	02/36
NCT05172596 / 2021-003747-22: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma	Active, not recruiting	2	147	Europe, Canada, Japan, US, RoW	PHE885	Novartis Pharmaceuticals, Novartis Pharma AG	Multiple Myeloma	06/25	06/25
NCT04318327: BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma	Active, not recruiting	1	96	US, RoW	PHE885	Novartis Pharmaceuticals	Multiple Myeloma	02/26	02/26